Implantable contraception

European Journal of Contraception and Reproductive Health Care

Volumn 5, Issue SUPPL. 2, 2000, Pages 2-11

  Darney, P D ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Etonogestrel; Injectable progestogens; Levonorgestrel; Medroxyprogesterone acetate; Oral contraception; Progestogen only implants

Indexed keywords

ANDROGEN; ELCOMETRINE; ETHYLENE VINYL ACETATE COPOLYMER; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; POLYMER;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANT; DRUG SAFETY; ECTOPIC PREGNANCY; FEMALE; GESTAGEN BLOOD LEVEL; HORMONAL CONTRACEPTION; HUMAN; MENSTRUATION DISORDER; ORAL CONTRACEPTION; OVARY FOLLICLE; OVARY FUNCTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION; TREATMENT FAILURE; TREATMENT OUTCOME;

CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; FEMALE; HUMANS; PATIENT SATISFACTION; PROGESTERONE CONGENERS; VINYL COMPOUNDS;

EID: 0034468297     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Single administration of hormones for long term control of reproductive function
2. Facts about an implantable contraceptive
3. One-year experience with subdermal contraceptive implants in the United States
4. Release rates of levonorgestrel from silastic capsules, homogenous rods and covered rods in humans
5. Levonorgestrel. Clinical pharmacokinetics
6. Contraceptive implants
7. Implantable contraceptives
8. Contraceptive implants
9. Subdermal contraceptive implants
10. Pharmacokinetics of Implanon®: An integrated analysis
11. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant)
12. Evaluation of a 1-year levonorgestrel-releasing contraceptive implant: Side effects, release rates and biodegradability
13. Clinical results with subcutaneous implants containing 3-keto desogestrel
14. Clinical trial with 3-keto-desogestrel subdermal implants
15. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant
16. A review of the effects of long-acting progestogen-only contraceptives on ovarian activity
17. Norplant® implants: The mechanism of contraceptive action
18. Anovulatory, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants
19. Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro
20. The pharmacodynamics and efficacy of Implanon®. An overview of the data
21. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel
22. Contraceptive failure in the United States: An update
23. Pre-introductory clinical trials of Norplant® implants: A comparison of seventeen countries' experience
24. Contraception with Norplant® implants
25. Clinical performance of a new two-rod levonorgestrel contraceptive implant: A three-year randomized study with Norplant® implants as controls
26. First week drug concentrations in women with levonorgestrel rod or Norplant® capsule implants
27. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants
28. The economic value of contraception: A comparison of 15 methods
29. Hormonal effects of the 300 μg norethisterone (NET) minipill. 1. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration
30. Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera)
31. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel
32. Estrogenic activity in women receiving an injectable progestogen for contraception
33. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant® use
34. Ovulatory dysfunction during continuous administration of lowdose levonorgestrel by subdermal implants
35. The clinical performance of Norplant® implants over time: A comparison of two cohorts
36. Ovarian endocrine function through five years of continuous treatment with Norplant subdermal contraceptive implants
37. Clinical trial with Nestorone subdermal contraceptive implants
38. Bleeding and serum d-norgestrel, estradiol and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception
39. The pharmacokinetics and pharmacodynamics of Implanon®, a single-rod etonogestrel female contraceptive implant
40. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception
41. Twenty-four month comparison of apolipoproteins A-I, A-II, and B in contraceptive implants users (Norplant® and Implanon®) in Birmingham, United Kingdom
42. International experience with Norplant® and Norplant-2® contraceptives
43. Clearance of LNG from the circulation after removal of Norplant
44. Levonorgestrel capsule implants in the United States: A 5-year study
45. Instruments versus fingers for removing contraceptive implants (Norplant®)
46. Ultrasound characteristics of subdermally implanted Implanon™ contraceptive rods
47. The 'pop-out' method of Norplant removal
48. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon®
49. Bleeding complaints during the first year of Norplant® implants use and their impact on removal rate
50. Experience with Depo-Provera as an injectable contraceptive
51. Phase III clinical trial with Norplant®II (two covered rods). Report of five years of use
52. Norplant 2 subdermal contraceptive system: Experience in Taiwan
53. The analysis of vaginal bleeding patterns induced by fertility regulating methods
54. The analysis of menstrual bleeding patterns: A review
55. Acceptance and perceptions of Norplant among users in San Francisco, USA
56. Impact of patient counselling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom
57. Changes in the menstrual bleeding of users of a subdermal contraceptive implant of nomegestrol acetate (Uniplant) do not influence sexual frequency, sexual desire, or sexual enjoyment
58. Patologia anexial no inflamatoria durante el uso de implantes de levonorgestrel o dispositivos intrauterinos
59. Progestin-only oral contraception: A comprehensive review